Proving the strategic value of patients

This webinar focuses on the benefits of integrated pharma manufacturing using examples of integrated processing and packaging solutions. The webinar also highlights the key advantages of choosing a single pharma solutions provider for all manufacturing needs.

As we approach the end of a year which saw global vaccine rollout for COVID-19, 44 novel drug approvals (to date) and the return of the CPHI Worldwide in-person event, we’re looking ahead to what 2022 has in store for the pharma industry.

Patient-centricity gets a lot of buzz, but what are the benefits of involving patients in the planning of a clinical trial?

Enabling formulations becomes more and more necessary to obtain adequate exposure of APIs during (pre)-clinical research. Currently, most registered formulations to improve bioavailability are based on lipidic systems, which make use of intrinsic digestion processes within the GI tract, facilitating the absorption of APIs. Aside from a general absorption mechanism, lipidic systems can also promote lymphatic transport of poorly soluble drugs, such as hormones. In addition, many different indications, such as HIV therapy, oncology, immunosuppressant and even arising therapies related to medicinal cannabis (e.g. CBD) can benefit from lipid formulations. These formulations create multiple possibilities for oral administration because they can be manufactured as solutions, suspensions, emulsions, and self-(micro)emulsifying systems.